

A multi-centre, randomised, double-blind, placebo controlled clinical trial examining the efficiency and safety of multi-vitamin therapy in secondary stroke prevention

Submission date 22/05/2003	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 22/05/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 11/07/2014	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Kennedy R Lees

Contact details
Department of Medicine & Therapeutics
Gardiner Institute
Western Infirmary
44 Church Street
Glasgow
United Kingdom
G11 6NT
krl1r@clinmed.gla.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00097669

Protocol serial number
G0200583

Study information

Scientific Title

Acronym

VITATOPS

Study objectives

To determine whether the addition of vitamin supplement (folate 2 mg, B6 25 mg, B12 500 µg) to best medical/surgical management (including modification of risk factors) will reduce the combined incidence of recurrent vascular events (stroke, myocardial infraction) and vascular death in patients with recent stroke or transient ischaemic attack (TIA).

Secondary objectives:

1. To determine whether the addition of vitamin supplements (folate 2 mg, B6 25 mg, B12 500 µg) will reduce:

a) The incidence of revascularisation procedures of the coronary, cerebral and peripheral circulations

b) Incidence of dementia and depression in patient with recent stroke or TIA

c) Occurrence of TIA in patients with recent stroke or TIA

2. To determine whether the effect of adding vitamin supplements (folate 2 mg, B6 25 mg, B12 500 µg) on the incidence of the primary outcome event (stroke, MI or vascular death) is consistent in patient subgroups such as those of different ethnicity and genotype.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multicentre randomised double-blind placebo-controlled clinical

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cardiovascular

Interventions

Multivitamins folate 2 mg, B6 25 mg, B12 500 µg or placebo

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Multivitamins folate, B6, B12

Primary outcome(s)

The primary outcome event is the composite event 'stroke, myocardial infarction, or death from any vascular cause', whichever occurs first.

Key secondary outcome(s)

Secondary outcome measures include TIA, depression, dementia, unstable angina, revascularisation procedures of the coronary, cerebral and peripheral circulations.

Completion date

31/07/2010

Eligibility**Key inclusion criteria**

All patients presenting to one of the participating neurologists or general physicians within 7 months of stroke (ischaemic or haemorrhagic) or transient ischemic attack (TIA) (eye or brain) are eligible for this trial.

In addition the patient must:

1. Agree to take study medications
2. Be geographically accessible for follow up
3. Provide written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Taking folate or vitamin B6, on medical advice
2. Use of vitamin supplements containing B6, B12 or Folate (unless patient agrees to take study medication instead of the vitamin supplements which they usually take)

3. Taking Methotrexate for any reason
4. Pregnancy or women of child-bearing potential who are at risk of pregnancy
5. Limited life expectancy

Date of first enrolment

01/07/2003

Date of final enrolment

31/07/2010

Locations

Countries of recruitment

United Kingdom

Scotland

Australia

Austria

Belgium

Brazil

Georgia

Hong Kong

India

Italy

Malaysia

Moldova

Netherlands

New Zealand

Pakistan

Philippines

Portugal

Serbia

Singapore

Sri Lanka

United States of America

Study participating centre
Department of Medicine & Therapeutics
Glasgow
United Kingdom
G11 6NT

Sponsor information

Organisation
University of Glasgow and Greater Glasgow Health Board (UK)

ROR
<https://ror.org/05kdz4d87>

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2010		Yes	No
Results article	cancer sub-study results	01/06/2012		Yes	No
Results article	results	01/06/2012		Yes	No
Results article	MRI sub-study results	01/12/2012		Yes	No
Results article	osteoporotic fractures sub-study results	03/09/2013		Yes	No
Protocol article	protocol	01/04/2002		Yes	No
Other publications	secondary analysis	01/08/2013		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes